Heart Failure | Reduced Ejection Fraction | Treatment Algorithms: Claims Data Analysis | US | 2025

Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the first-line treatment, usually in combination with diuretics when fluid overload is present. The addition of a second- or third-line treatment is often needed to better manage the disease. Given the heavily genericized nature of the market, branded agents have had difficulty establishing a foothold. However, the use of Entresto (sacubitril / valsartan) and SGLT-2 inhibitors has grown steadily since their launch. This report provides important insight into how these agents are used in the management of HFrEF and how practices are evolving.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
• How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson Innovative Medicine, Eli Lilly, Boehringer Ingelheim, Amgen

Key drugs: ACE inhibitors, ARBs, beta blockers, MRAs, diuretics, CCBs, nitrates, ivabradine, vericiguat, Entresto (sacubitril / valsartan), SGLT-2 inhibitors

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.